HCA Healthcare, Inc. $HCA Shares Sold by USS Investment Management Ltd

Key Points

• USS Investment Management Ltd has reduced its stake in HCA Healthcare by 18.9%, now holding 29,595 shares valued at approximately $10.24 million.
• HCA Healthcare reported $6.84 EPS for the last quarter, exceeding estimates, with revenue of $18.61 billion, up 6.4% year-over-year.
• The firm declared a quarterly dividend of $0.72 per share, with a payout ratio of 12.11%, to be paid on September 30th.

USS Investment Management Ltd trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 18.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,595 shares of the company's stock after selling 6,900 shares during the period. USS Investment Management Ltd's holdings in HCA Healthcare were worth $10,240,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in HCA. Brown Advisory Inc. boosted its position in shares of HCA Healthcare by 53.9% in the first quarter. Brown Advisory Inc. now owns 4,630 shares of the company's stock worth $1,600,000 after buying an additional 1,622 shares during the period. Farther Finance Advisors LLC boosted its position in shares of HCA Healthcare by 26.9% in the first quarter. Farther Finance Advisors LLC now owns 1,141 shares of the company's stock worth $395,000 after buying an additional 242 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of HCA Healthcare by 2.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 4,314 shares of the company's stock worth $1,491,000 after buying an additional 105 shares during the period. GAMMA Investing LLC boosted its position in shares of HCA Healthcare by 17.6% in the first quarter. GAMMA Investing LLC now owns 4,931 shares of the company's stock worth $1,704,000 after buying an additional 737 shares during the period. Finally, J.W. Cole Advisors Inc. boosted its position in shares of HCA Healthcare by 145.3% in the first quarter. J.W. Cole Advisors Inc. now owns 3,550 shares of the company's stock worth $1,227,000 after buying an additional 2,103 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Trading Up 2.2%

Shares of NYSE HCA opened at $420.68 on Monday. The stock's 50 day moving average price is $380.14 and its two-hundred day moving average price is $360.39. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $420.98. The stock has a market capitalization of $98.43 billion, a P/E ratio of 17.68, a PEG ratio of 1.32 and a beta of 1.41. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $18.61 billion for the quarter, compared to analysts' expectations of $18.49 billion. During the same quarter in the prior year, the firm posted $5.50 earnings per share. HCA Healthcare's revenue for the quarter was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is currently 12.11%.

Analysts Set New Price Targets

Several analysts have recently weighed in on HCA shares. JPMorgan Chase & Co. raised their target price on HCA Healthcare from $360.00 to $370.00 and gave the company a "neutral" rating in a research note on Monday, August 4th. Barclays lowered their target price on HCA Healthcare from $416.00 to $390.00 and set an "overweight" rating for the company in a research note on Monday, July 28th. Wall Street Zen upgraded HCA Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Morgan Stanley lowered their target price on HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research note on Monday, July 28th. Finally, Wolfe Research downgraded HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, HCA Healthcare presently has an average rating of "Moderate Buy" and a consensus target price of $401.83.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.